Pretty sure drug approval is more onerous than a diagnostic test.
Not a Pollyanna, but once you shake off today's earnings disappointment, you realize we are suprisingly close to where we thought we would be 9 months ago.
Wrong time and price to jump ship in my opinion.
On the bright side, we are about a month away from completing the Troponin study and two months away from FDA submission. The 3rd Q earnings call in October could very well be quite positive.
They've got a ton of cash. This could be the last great buying opportunity.
"Canadiens", that's the French spelling. Either way be careful, especially in the mining and software sectors.
Great hockey players though. And yes, I do like MITL here.
I wouldn't hang my hat on any of those three things happening.
The best thing this story has going for it is the recent purchases by Fosun.
It is also cheap on depressed earnings and pays a nice dividend.
Organic growth has been flat to negative the last few years. Growth through acquisition requires cash, not sure buying back stock makes much sense.
This is an important comment. Who has the fiduciary responsibility to look out for shareholders? Clearly, it is not the external advisor, Prospect Capital Management.
Some one in a fiduciary capacity has to blow the whistle on the exorbitant fees.